EPCAM and carcinoma: EpCAM-ReTARGTPR showed potent in vitro capacity to redirect anti-CMVpp65 CD8pos T cells from CMV-seropositive/HLA-B*07:02pos donors to selectively eliminate various EpCAM-expressing carcinoma cell lines and primary patient-derived cancer cells [4].